Company
United StatesPublic company, NASDAQ: RGENRepligen Corporation (NASDAQ: RGEN), Waltham, MA – FDA Inspections
Inspection records and compliance data for Repligen Corporation in Waltham, Massachusetts. 1 FDA inspection on record, last inspected February 29, 2012. Publicly traded as NASDAQ: RGEN.
Company Profile
This profile covers Repligen Corporation based in Waltham, Massachusetts, United States.
FDA Inspection History
- FDA inspections
- 1
- OAI
- 0
- VAI
- 0
- NAI
- 1
- Form 483s
- 0
- Warning letters
- 0
Inspected February 29, 2012.
FDA inspections (1)
| Date | Result | FDA center(s) | Insp. # |
|---|---|---|---|
| February 29, 2012 | NAI | Human Drugs · Bioresearch Monitoring | 772899 |
FDA documents
No Form 483s, Warning Letters or EIRs on record.
Related Companies (10)
Companies with similar regulatory profiles, compliance history, and operations.
Company Information
Name
Repligen Corporation
Stock ticker
RGEN
Exchange
NASDAQ
Share price
$168.39
Market cap
$10.8B
Price as of
November 6, 2026
FEI Number
3009352682
Address
41 Seyon St, Building 1, Suite 100, Waltham, Massachusetts 02453, United States
Country
United States
ID: a29f4304-4976-4249-b621-d474242cb1d9